EOLS does not have "huge capital expenditure" because Jeuveau is manufacted by a third party (Daewoong). EOLS does have significant marketing and selling expenses, but that's a different animal.
If EOLS had a superior product, they could easily be profitable within seven months of the product launch. But Jeuveau is essentially just Botox in a new pink package.
Lots of Serious Side Effects that are labeled with this drug application. Future and potential lawsuits still loom for at least the first year as well...